Literature DB >> 12479859

A polymorphism in the angiogenesis inhibitor, endostatin, in multiple myeloma.

Manoela M Ortega, Helvia Nascimento, Fernando F Costa, Maria T Teori, Carmen S P Lima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12479859     DOI： 10.1016/s0145-2126(02)00218-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Genetic polymorphisms in COL18A1 influence the development of osteosarcoma.

Authors:  Zhihao Guo; Tianji Zhang; Juntao Wu; Hongwei Wang; Xiaotan Liu; Linqiang Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  The S2 subsites of cathepsins K and L and their contribution to collagen degradation.

Authors:  Fabien Lecaille; Shafinaz Chowdhury; Enrico Purisima; Dieter Brömme; Gilles Lalmanach
Journal:  Protein Sci       Date:  2007-04       Impact factor: 6.725

3.  Genotype analysis of the human endostatin variant p.D104N in benign and malignant adrenocortical tumors.

Authors:  Beatriz Marinho de Paula Mariani; Ericka Barbosa Trarbach; Tamaya Castro Ribeiro; Maria Adelaide Albergaria Pereira; Berenice Bilharinho Mendonca; Maria Candida Barisson Villares Fragoso
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

4.  Endostatin gene variation and protein levels in breast cancer susceptibility and severity.

Authors:  Sabapathy P Balasubramanian; Simon S Cross; Jenny Globe; Angela Cox; Nicola J Brown; Malcolm W Reed
Journal:  BMC Cancer       Date:  2007-06-22       Impact factor: 4.430

5.  A high risk of osteosarcoma in individuals who are homozygous for the p.D104N in endostatin.

Authors:  Wen-Zhi Bi; Dian-Wei Li; Song Luo; Zhi-Gang Song; Yun Wang; Hua Jin; Yan Wang; Qing Li; Meng-Xia Li; Dong Wang; Bo Sun; Meng Xu; Cheng-Xiong Xu
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.